YLR171W Antibody

What is YLR171W and what experimental systems is the YLR171W antibody validated for?

YLR171W is a protein from Saccharomyces cerevisiae (baker's yeast, strain ATCC 204508/S288c). The YLR171W antibody (CSB-PA515557XA01SVG) is a polyclonal antibody raised in rabbits against recombinant Saccharomyces cerevisiae YLR171W protein. This antibody has been validated for ELISA and Western Blot applications to ensure proper identification of the target antigen. The antibody specifically reacts with Saccharomyces cerevisiae (strain ATCC 204508/S288c) .

For experimental systems, researchers should note this antibody is specifically designed for yeast research applications. When planning experiments, it's important to remember that this antibody has not been validated for other species or additional applications beyond those specified in the product documentation.

What are the optimal storage conditions for maintaining YLR171W antibody activity?

The YLR171W antibody should be stored at -20°C or -80°C immediately upon receipt. Researchers should avoid repeated freeze-thaw cycles as these can significantly degrade antibody quality and performance. The antibody is provided in liquid form, suspended in a storage buffer containing 0.03% Proclin 300 as a preservative, 50% Glycerol, and 0.01M PBS at pH 7.4 .

For long-term storage planning, consider the following protocol:

• Aliquot the antibody into smaller volumes based on typical experimental usage

• Store primary aliquots at -80°C for maximum stability

• Keep working aliquots at -20°C

• Document freeze-thaw cycles for each aliquot

• Include positive controls in experiments after extended storage periods to verify activity

How should researchers validate the YLR171W antibody specificity before experimental use?

Antibody validation is critical to ensure experimental reproducibility. For YLR171W antibody, researchers should implement a multi-step validation strategy:

• Knockout control validation: Use YLR171W knockout yeast strains as negative controls in Western blot and other applications. This approach has been demonstrated to be superior for validation compared to other control types .

• Positive control testing: Include a known positive sample containing the target protein at a verified concentration.

• Cross-reactivity assessment: Test the antibody against related yeast strains or species to verify specificity.

• Concentration optimization: Perform titration experiments to determine the optimal antibody concentration for each experimental system and application.

• Validation across multiple lots: If possible, compare performance across different antibody lots.

This rigorous validation approach aligns with current best practices in antibody characterization, which helps address the estimated 50% failure rate of commercial antibodies to meet basic characterization standards .

What controls are essential when using YLR171W antibody in Western blot applications?

For rigorous Western blot experiments with YLR171W antibody, researchers should include the following controls:

• Knockout control: Lysate from YLR171W knockout yeast strain (most critical control)

• Positive control: Wild-type yeast lysate with known YLR171W expression

• Loading control: Probing for a housekeeping protein (e.g., actin) to normalize expression

• Specificity control: Secondary antibody only control to identify non-specific binding

• Molecular weight marker: To confirm target band appears at expected size

The inclusion of knockout controls is particularly important as research has demonstrated they are superior to other control types for Western blots. A recent comprehensive study by the YCharOS group revealed that the use of knockout cell lines provides the most reliable validation for antibodies in Western blot applications, significantly reducing false positive results .

How should researchers determine the optimal antibody concentration for different experimental applications?

Determining optimal antibody concentration requires methodical titration across applications:

For Western Blot applications:

• Start with a concentration range of 0.1-2 μg/mL (based on the antibody's protein concentration, not dilution factor)

• Prepare a dilution series (e.g., 0.1, 0.5, 1.0, and 2.0 μg/mL)

• Run identical Western blots with each concentration

• Evaluate signal-to-noise ratio at each concentration

• Select the lowest concentration that provides clear specific signal with minimal background

For ELISA applications:

• Prepare a matrix titration with varying antigen concentrations

• Test antibody concentrations from 0.1-5 μg/mL

• Generate a standard curve for each concentration

• Select the concentration that provides the widest dynamic range with lowest background

When reporting methods, always specify the actual protein concentration used rather than dilution factors, as dilution values without knowing the stock concentration are ambiguous and hinder reproducibility .

What methodological modifications are needed when using the YLR171W antibody across different yeast growth conditions?

When investigating YLR171W across varying growth conditions, researchers should consider these methodological adaptations:

• Sample preparation optimization:

  • For stationary phase cells: Extend lysis time by 15-20% due to thickened cell walls

  • For nutrient-limited conditions: Increase cell numbers by 25-50% to compensate for potential reduced protein expression

  • For different carbon sources: Adapt extraction buffers to account for altered membrane composition

• Validation across conditions:

  • Generate condition-specific standard curves for quantitative applications

  • Verify antibody specificity separately for each growth condition

  • Include biological replicates that span the full range of tested conditions

• Protocol modifications:

  • Adjust blocking buffers based on carbon source used (glucose vs. alternative carbon sources)

  • Consider extended primary antibody incubation times for complex samples

  • Implement gradient gels when comparing samples across growth phases to account for potential post-translational modifications

These methodological adaptations ensure detection sensitivity remains consistent across experimental conditions, preventing misinterpretation of results due to technical variables rather than biological differences.

How can researchers optimize immunoprecipitation protocols with the YLR171W antibody for protein interaction studies?

While YLR171W antibody is not explicitly validated for immunoprecipitation, researchers investigating protein interactions might adapt it for this purpose with specific optimization steps:

• Pre-clearing optimization:

  • Pre-clear lysates with protein A/G beads for 1 hour at 4°C

  • Include 0.1% Triton X-100 in washing buffer to reduce non-specific binding

  • Validate with knockout controls to establish specificity baseline

• Cross-linking considerations:

  • If using cross-linking, optimize formaldehyde concentration (0.1-1%) and exposure time

  • Include a glycine quenching step (125mM final concentration)

  • Verify cross-linking efficacy with pilot experiments

• Antibody coupling strategy:

  • Direct coupling to beads (recommended for cleaner results):
    a. Use commercially available coupling kits with activated beads
    b. Optimize antibody-to-bead ratio (typically 5-10 μg antibody per 50 μL bead slurry)
    c. Verify coupling efficiency by measuring protein concentration pre- and post-coupling

• Validation hierarchy:

  • Validate interactions with reciprocal IPs using antibodies against suspected interacting partners

  • Confirm with orthogonal methods (e.g., proximity ligation assay)

  • Include wild-type and knockout controls in all experiments

Research has demonstrated that recombinant antibodies generally outperform both monoclonal and polyclonal antibodies in multiple assays . Since YLR171W antibody is polyclonal, researchers should be particularly rigorous in validation and consider developing or obtaining recombinant alternatives for critical interaction studies.

What strategies should be employed to reconcile contradictory results between different batches of YLR171W antibody?

Batch-to-batch variation is a significant challenge in antibody research. When confronting contradictory results between antibody batches, implement this systematic approach:

• Comprehensive validation comparison:

  • Perform side-by-side Western blots with both batches using identical samples

  • Include knockout controls for each batch

  • Generate titration curves for each batch to determine sensitivity differences

• Epitope mapping investigation:

  • Analyze if differential results suggest recognition of distinct epitopes

  • Consider peptide competition assays to identify specific binding regions

  • Evaluate if post-translational modifications might affect epitope recognition

• Standardization protocol:

  • Normalize results based on calibration curves generated with recombinant target protein

  • Establish batch correction factors based on quantitative performance metrics

  • Document and report batch information in publications using Research Resource Identifiers (RRIDs)

• Decision matrix:

This structured approach not only helps reconcile results but contributes to the broader effort to improve antibody reproducibility in the research community, addressing the estimated billions in losses due to antibody variability .

How can advanced microscopy techniques be optimized for YLR171W localization studies?

Although immunofluorescence is not listed among the validated applications for this antibody, researchers pursuing advanced localization studies should consider these methodological adaptations:

• Fixation optimization:

  • Compare formaldehyde (3-4%) and methanol fixation protocols

  • Optimize fixation time (10-30 minutes) to balance structure preservation and epitope accessibility

  • For yeast cells, include cell wall digestion step with zymolyase (optimize concentration and time)

• Signal amplification strategies:

  • Implement tyramide signal amplification for weak signals

  • Consider secondary antibody with higher fluorophore conjugation ratio

  • Evaluate quantum dot-conjugated secondary antibodies for photostability

• Colocalization verification:

  • Use spectrally distinct markers for organelle identification

  • Apply Pearson correlation coefficient analysis for quantitative colocalization

  • Implement super-resolution techniques (STED, PALM) for high-precision localization

• Validation methodology:

  • YLR171W knockout controls are absolutely essential

  • Include competition assays with immunizing peptide

  • Verify localization with orthogonal methods (e.g., fractionation + Western blot)

Recent research has demonstrated that knockout cell lines are even more critical for validating antibodies in immunofluorescence applications than in Western blots, as background and non-specific binding can significantly impact imaging results .

What are the most effective troubleshooting approaches for inconsistent Western blot results with YLR171W antibody?

When facing inconsistent Western blot results, implement this systematic troubleshooting framework:

• Sample preparation assessment:

  • Verify complete lysis with microscopy

  • Ensure protease inhibitors are fresh and active

  • Compare different lysis buffers (RIPA vs. NP-40 vs. Triton-based)

  • Standardize protein quantification method

• Technical parameter optimization:

  • Adjust transfer conditions (time, voltage, buffer composition)

  • Optimize blocking agents (BSA vs. milk, concentration)

  • Test multiple membrane types (PVDF vs. nitrocellulose, pore sizes)

  • Standardize incubation temperatures and times

• Antibody-specific considerations:

  • Prepare fresh antibody dilutions from stock

  • Test different antibody concentrations (0.1-2 μg/mL range)

  • Evaluate alternative detection systems

  • Consider additives to reduce non-specific binding (0.1% Tween-20)

• Standardization approach:

  • Include internal calibration samples in each blot

  • Document all protocol parameters systematically

  • Implement positive and negative controls in each experiment

This structured approach aligns with best practices documented in antibody characterization studies, where standardized protocols and comprehensive controls were shown to significantly improve reproducibility across laboratories .

How should researchers distinguish between true YLR171W signal and non-specific binding in complex experimental systems?

Differentiating specific from non-specific signals requires a multi-faceted approach:

• Essential control experiments:

  • YLR171W knockout control (gold standard)

  • Secondary antibody-only control

  • Pre-immune serum control (if available)

  • Competitive inhibition with immunizing peptide

• Signal characteristics analysis:

  • Evaluate signal at expected molecular weight (compare with predicted MW)

  • Assess signal consistency across experimental replicates

  • Compare signal pattern with published literature data

  • Analyze signal response to expected biological manipulations

• Quantitative validation approach:

  • Calculate signal-to-noise ratios across samples

  • Implement statistical threshold criteria for positive signal identification

  • Perform dose-response experiments with recombinant protein standards

• Decision framework for signal validation:

Recent research has shown that approximately 12 publications per protein target included data from antibodies that failed to recognize the relevant target protein , highlighting the critical importance of rigorous validation before data interpretation.

What quantitative approaches can accurately normalize YLR171W expression data across different experimental conditions?

For robust quantitative analysis of YLR171W expression, implement these normalization strategies:

• Internal reference standardization:

  • Use multiple housekeeping proteins (at least three) for normalization

  • Verify stability of reference proteins across experimental conditions

  • Calculate geometric mean of multiple references for more robust normalization

• Total protein normalization methods:

  • Implement stain-free technology for total protein measurement

  • Use reversible total protein stains (Ponceau S, SYPRO Ruby)

  • Compare results across different normalization approaches

• Standard curve implementation:

  • Generate standard curves using recombinant YLR171W protein

  • Include standard curve samples on each experimental blot

  • Calculate absolute quantities rather than relative values when possible

• Advanced computational approaches:

  • Apply LOESS normalization for non-linear signal response

  • Implement variance stabilization for heteroscedastic data

  • Use Bayesian hierarchical models for complex experimental designs

These quantitative approaches address the significant challenges in data interpretation highlighted by antibody characterization initiatives, which found that inadequate controls and normalization methods contributed significantly to poor reproducibility in antibody-based experiments .

What information must researchers include when reporting YLR171W antibody usage in scientific publications?

To ensure reproducibility and transparency in antibody-based experiments, researchers must include:

• Complete antibody identification:

  • Vendor name and location (e.g., Cusabio)

  • Catalog number (CSB-PA515557XA01SVG)

  • Research Resource Identifier (RRID) if available

  • Lot number used in experiments

  • Antibody type (polyclonal, raised in rabbit)

  • Target species (Saccharomyces cerevisiae strain ATCC 204508/S288c)

• Detailed methodological parameters:

  • Antibody concentration used (in μg/mL, not just dilution factor)

  • Incubation conditions (time, temperature, buffer composition)

  • Blocking reagents and conditions

  • Detection method specifications

  • Complete protocol or reference to published protocol

• Validation information:

  • Controls used (especially knockout controls)

  • Optimization experiments performed

  • Previous validation citations if available

  • Any observed limitations or cross-reactivity

Research has demonstrated that inadequate reporting of antibody details significantly hinders reproducibility. The scientific community and journals are increasingly implementing standardized reporting requirements to address this issue .

How can researchers contribute to improving the reproducibility of YLR171W antibody-based research in the scientific community?

Researchers can contribute to better reproducibility through:

• Community validation contribution:

  • Share detailed validation data in repositories

  • Participate in collaborative characterization initiatives

  • Report both positive and negative results to antibody vendors

  • Contribute to open antibody validation databases

• Methodological standardization:

  • Adopt consensus protocols for common applications

  • Implement rigorous control experiments

  • Use recombinant antibodies when available

  • Follow standardized reporting guidelines

• Training and education:

  • Ensure proper training for all lab members in antibody techniques

  • Attend workshops on antibody validation

  • Incorporate reproducibility discussions in lab meetings

  • Develop standard operating procedures for antibody usage

These approaches align with recommendations from scientific organizations addressing the "antibody characterization crisis," estimated to cost billions in wasted research funds annually. By implementing these practices, researchers can help transform the research culture toward greater reproducibility and reliability .

How do recombinant antibody alternatives compare to the polyclonal YLR171W antibody for research applications?

Recombinant antibody technology offers several advantages over traditional polyclonal antibodies like the YLR171W antibody:

• Performance comparison:

  • Recombinant antibodies demonstrate superior batch-to-batch consistency

  • Recent studies show recombinant antibodies outperform both monoclonal and polyclonal antibodies across multiple assay types

  • Epitope specificity can be precisely engineered in recombinant systems

• Methodological differences:

  • Recombinant antibodies eliminate animal-to-animal variation inherent in polyclonal production

  • Sequence-defined antibodies allow exact reproduction in different laboratories

  • Production can be scaled without quality concerns

• Application-specific considerations:

  • For Western blots: Recombinant antibodies typically provide cleaner backgrounds

  • For immunoprecipitation: Higher specificity enables detection of lower abundance interactors

  • For quantitative applications: Better linearity of response improves accuracy

• Decision framework for antibody selection:

The scientific community is increasingly moving toward recombinant antibodies as the gold standard for research applications, with some experts advocating that only recombinant antibodies should be used in the long term to address reproducibility challenges .

What alternative methods can complement or validate YLR171W antibody-based findings in yeast research?

• Genetic tagging strategies:

  • C-terminal or N-terminal epitope tagging (HA, FLAG, GFP)

  • CRISPR-Cas9 endogenous tagging

  • Auxin-inducible degron system for functional validation

  • Split-GFP complementation for interaction studies

• Orthogonal detection methods:

  • Mass spectrometry-based proteomics

  • RNA-based approaches (RT-qPCR, RNA-seq)

  • Activity-based protein profiling

  • Proximity-dependent labeling (BioID, APEX)

• Functional validation approaches:

  • Genetic deletion phenotypes

  • Complementation assays

  • Structure-function analysis with domain mutations

  • Heterologous expression systems

• Integration framework for multi-modal validation: